FINWIRES · TerminalLIVE
FINWIRES

Citigroup Downgrades ResMed to Neutral From Buy, Adjusts Price Target to $235 From $270

By

ResMed (RMD) has an average rating of overweight and mean price target of $269.05, according to analysts polled by FactSet.

What else is happening in Research?